Percutaneous edwards SAPIEN<sup>™</sup> valve implantation for significant pulmonary regurgitation after previous surgical repair with a right ventricular outflow patch

Demkow, Marcin; Rużyłło, Witold; Biernacka, Elżbieta Katarzyna; Kalińczuk, Łukasz; Śpiewak, Mateusz; Kowalski, Mirosław; Sitkowska, Ewa; Kuśmierczyk, Mariusz; Różański, Jacek; Banaś, Sławomir; Chmielak, Zbigniew; Hoffmań, Piotr

doi:10.1002/ccd.25096

Cited by 42 publications

(32 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Their size range from 20 to 29 mm and this allows for broader indications; the XT valves are all delivered through a NovaFlex delivery system whereas the Sapien 3 uses the Commander delivery system [3][4][5][6][7]. The technique is well established.…”

Section: Resultsmentioning

confidence: 99%

Untitled

DeGiovanni¹

2016

jshd

View full text Add to dashboard Cite

Pulmonary valve replacement is one of the most common surgical procedures performed in older children and adults with congenital heart disease who have normally had at least one previous operation. The percutaneous alternative was first performed in man in 2000 when Dr. Bonhoeffer merged a surgically available bovine jugular vein valve (Venpro/Contegra) and a Cheatham-Platinum (CP) stent to create a percutaneous system for stenosed conduits; this valve was subsequently acquired by Medtronic and is now the Melody valve. The Edwards Sapien valve was originally designed for percutaneous aortic valve replacement (TAVI/TAVR), but its design makes it equally suitable for pulmonary implantation using a similar delivery system and it is indeed indicated for this purpose [1, 2]. The Edwards valve has evolved over recent years, increasing the range of sizes including the 29-mm Edwards XT and, more recently, the Sapien 53. The Edwards 3, incorporates a cuff/skirt outside of the frame to minimize paravalvular leaks; it was primarily designed for the aortic position where paravalvular leaks are generally more significant. Follow-up observations indicate that the performance and longevity of the Edwards percutaneous valve are comparable to surgically implanted bioprostheses which are also manufactured by Edwards Lifesciences; the catheter technique has reached a high level of sophistication to achieve successful and safe results in selected individuals. Some patients, however, would be better candidates for surgery, usually for anatomic reasons. Transcatheter pulmonary valve implantation has some advantages over surgery, as it is less invasive, avoids repeat sternotomy and bypass, does not usually require intensive care, and results in a shorter hospital stay. Cost effectiveness is comparable, and because the Edwards valve is based on a well-established tissue valve technology, its longevity are performance are expected to be similar to that of surgery as the frame on which the valve is mounted is very robust with complete integrity maintained over at least 5 years from implantation.

show abstract

Section: Resultsmentioning

confidence: 99%

Untitled

DeGiovanni¹

2016

jshd

View full text Add to dashboard Cite

show abstract

“…Since then, considerable experience has been gained in this field, with both the Melody valve and the ESV. [37][38][39][40][41] Table 6 summarizes results of the pulmonary VIV procedure. …”

Section: Pulmonary Valve In Valvementioning

confidence: 99%

Valve-in-Valve Therapy for Failed Surgical Bioprosthetic Valves

Noorani

Bapat

2015

Interventional Cardiology Clinics

View full text Add to dashboard Cite

“…In all patients prestenting with a bare metal stent was performed to prepare a stiff landing zone for the valve. In case of borderline dimension of RVOT prestenting was performed 2 months before valve implantation [24]. …”

Section: Indications For Percutaneous Pulmonary Valve Implantation Anmentioning

confidence: 99%

“…There was no periprocedural mortality. In 2011 we extended indications for PPVI for patients with a native or patched RVOT [24]. In most of these patients the procedure of SAPIEN Edwards valve implantation was preceded by metal stenting 2 months earlier.…”

Section: Own Experiencementioning

confidence: 99%

Percutaneous pulmonary valve implantation – state of the art and Polish experience

Biernacka¹,

Rużyłło²,

Demkow³

2017

pwki

Self Cite

View full text Add to dashboard Cite

Percutaneous pulmonary valve implantation (PPVI) is a relatively new method of treating patients with right ventricular outflow tract (RVOT) dysfunction after surgical repair of congenital heart disease. Since its introduction in 2000 by Bonhoeffer, more than ten thousand PPVI procedures have been performed worldwide. Indications for PPVI have been adapted from those accepted for surgical intervention. Two types of valves are being used: Melody Medtronic available in diameters 16 mm and 18 mm and the family of Edwards SAPIEN valves 23, 26 and 29. The procedure has been shown to be feasible and safe when performed in patients with full pulmonary conduit dysfunction and in selected cases of patched RVOT. The low complication rate and the reduced number of open-chest re-interventions over a patient’s lifetime are among the main advantages of the procedure. The most important problem responsible for late mortality and reinterventions is infective endocarditis. Size restrictions of the currently available valves limit deployment in the majority of patients with a wide RVOT. Newer devices are being developed to make these patients suitable for PPVI. A literature review, Polish experience and results of PPVI performed in 66 patients in the Institute of Cardiology in Warsaw are briefly reported.

show abstract

Percutaneous edwards SAPIEN^™ valve implantation for significant pulmonary regurgitation after previous surgical repair with a right ventricular outflow patch

Cited by 42 publications

References 32 publications

Untitled

Untitled

Valve-in-Valve Therapy for Failed Surgical Bioprosthetic Valves

Percutaneous pulmonary valve implantation – state of the art and Polish experience

Contact Info

Product

Resources

About

Percutaneous edwards SAPIEN™ valve implantation for significant pulmonary regurgitation after previous surgical repair with a right ventricular outflow patch

Cited by 42 publications

References 32 publications

Untitled

Untitled

Valve-in-Valve Therapy for Failed Surgical Bioprosthetic Valves

Percutaneous pulmonary valve implantation – state of the art and Polish experience

Contact Info

Product

Resources

About

Percutaneous edwards SAPIEN^™ valve implantation for significant pulmonary regurgitation after previous surgical repair with a right ventricular outflow patch